Drug for preventing and treating myocardial injury caused by coronary microembolism and animal model thereof

A technique for myocardial injury and coronary artery disease, applied in drug combination, medical science, cardiovascular system diseases, etc., can solve the problems of incomplete understanding of molecular and immune mechanisms, decreased myocardial systolic function, etc., and achieve the effect of protecting myocardial injury

Inactive Publication Date: 2019-05-03
AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] To sum up, the problems existing in the prior art are: myocardial injury caused by coronary microembolism, myocardial systolic function progressively decreased, and its molecular and immune mechanisms are not yet fully understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for preventing and treating myocardial injury caused by coronary microembolism and animal model thereof
  • Drug for preventing and treating myocardial injury caused by coronary microembolism and animal model thereof
  • Drug for preventing and treating myocardial injury caused by coronary microembolism and animal model thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0034] In order to make the object, technical solution and advantages of the present invention more clear, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0035] Coronary Microembolization (CME) is a difficult complication in interventional treatment of coronary heart disease. The inflammatory response after CME is one of the main mechanisms causing myocardial injury. The immune and inflammatory response mediated by Toll-like receptor 4 (tolllike receptor4, TLR4) plays an important role in cardiovascular diseases. In the preliminary experiment, it was found that after CME, the expression of TLR4 gene was significantly increased, and the signal transduction pathway mediated was likely to be involved in the myocardial injury caused by CME. The present invention establishes a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention belongs to the technical field of preventing and treating coronary myocardial injury and discloses a drug for preventing and treating the myocardial injury caused by coronary microembolism and an animal model thereof; SD rats are used and 42 [mu]m microemboli are used to prepare the coronary microembolism CME animal model; after selecting CME, 3 h, 6 h, 9 h, 12 h and 24 h areused as observation time points, observation groups at each time points are divided into a sham operation group and a CME group, and expression levels and cardiac function changes of TLR4 at the eachtime point are detected to find out peak time of activity of the TLR4; according to the peak time point of the activity of the TLR4, then the sham operation group, the CME group, a CME+nicorandil group and a CME+TLR4 inhibitor group. The animal model determines dynamic changes of TLR4-mediated cell signal transduction pathways of "TLR4 / MyD88 / NF-kappa-B / TNF-alpha" after the CME occurrence and determines whether nicorandil blocks the "TLR4 / MyD88 / NF-kappa-B / TNF-alpha signaling pathways to protect against myocardial damages caused by the CME.

Description

technical field [0001] The invention belongs to the technical field of preventing and treating coronary artery myocardial injury, and in particular relates to a medicine and an animal model for preventing and treating myocardial injury caused by coronary microembolism. Background technique [0002] At present, the existing technology commonly used in the industry is as follows: Coronary microembolization (Coronary Microembolization, CME) is a coronary artery caused by spontaneous rupture of coronary atherosclerotic plaque or tiny embolism in the process of coronary intervention (Percutaneous Coronary Intervention, PCI). The incidence of microcirculation embolism and myocardial infarction is 15-20%, and it can be as high as 30-45% in high-risk patients. Studies have shown that: (1) CME can lead to "no blood flow" or "slow blood flow" immediately after surgery, which is a strong predictor of poor long-term prognosis and major adverse cardiac events; (2) CME often causes microc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/455A61P9/10A01K67/02A61D1/00
Inventor 苏强吕祥威叶自亮
Owner AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap